Literature DB >> 8408738

Differences of chronopharmacokinetic profiles between propranolol and atenolol in hypertensive subjects.

T Shiga1, A Fujimura, T Tateishi, K Ohashi, A Ebihara.   

Abstract

Previous studies have shown that the absorption rate of a lipophilic, but not hydrophilic, agent is faster after the night dosage than after the morning dosage in nocturnal rodents. The present study examines whether such a difference in chronopharmacokinetic profiles between lipophilic and hydrophilic agents also exists in humans. Propranolol (20 mg), a lipophilic beta-blocker, or atenolol (50 mg), a hydrophilic beta-blocker, was given orally to 13 hypertensive patients at 9:00 AM (day trial) or 9:00 PM (night trial) by a crossover design. Plasma concentrations of propranolol and its metabolites, 4-hydroxypropranolol and naphthoxylactic acid, and atenolol were determined just before and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, and 24 hours after treatment. Maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) of propranolol in the day trial were significantly greater than those in the night trial. Time to maximum plasma concentration (tmax) was significantly shorter in the day trial. No significant difference was observed in the elimination half-life between the two trials. There were similar administration time-dependent changes in the Cmax for 4-hydroxypropranolol and naphthoxylactic acid. On the other hand, although the Cmax of atenolol was greater and its tmax was shorter in the day trial, the differences did not reach significance. These results suggest that propranolol, but not atenolol is absorbed more rapidly after the morning dosage than after the night dosage. Based on these findings, the authors speculate that the absorption rate of a lipophilic, but not hydrophilic, agent is faster after the morning dosage than after the night dosage in humans.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8408738     DOI: 10.1002/j.1552-4604.1993.tb05620.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  7 in total

1.  Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine.

Authors:  B Olsson; J Szamosi
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 2.  Molecular clocks in pharmacology.

Authors:  Erik S Musiek; Garret A Fitzgerald
Journal:  Handb Exp Pharmacol       Date:  2013

3.  Chronopharmacology of enalapril in hypertensive patients.

Authors:  K Sunaga; A Fujimura; T Shiga; A Ebihara
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 4.  Evening versus morning dosing regimen drug therapy for hypertension.

Authors:  Ping Zhao; Ping Xu; Chaomin Wan; Zhengrong Wang
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

5.  Guidelines for the design and conduct of human clinical trials on ingestion-time differences - chronopharmacology and chronotherapy - of hypertension medications.

Authors:  Ramón C Hermida; Michael H Smolensky; Horia Balan; Richard J Castriotta; Juan J Crespo; Yaron Dagan; Sherine El-Toukhy; José R Fernández; Garret A FitzGerald; Akio Fujimura; Yong-Jian Geng; Ramón G Hermida-Ayala; Antonio P Machado; Luiz Menna-Barreto; Artemio Mojón; Alfonso Otero; R Daniel Rudic; Eva Schernhammer; Carsten Skarke; Tomoko Y Steen; Martin E Young; Xiaoyun Zhao
Journal:  Chronobiol Int       Date:  2020-12-20       Impact factor: 3.749

6.  Time of Administration of Acute or Chronic Doses of Imipramine Affects its Antidepressant Action in Rats.

Authors:  Hiroshi Kawai; Natsumi Kodaira; Chika Tanaka; Takuya Ishibashi; Naomi Kudo; Yoichi Kawashima; Atsushi Mitsumoto
Journal:  J Circadian Rhythms       Date:  2018-05-10

Review 7.  Timing of Administration: For Commonly-Prescribed Medicines in Australia.

Authors:  Gagandeep Kaur; Craig L Phillips; Keith Wong; Andrew J McLachlan; Bandana Saini
Journal:  Pharmaceutics       Date:  2016-04-15       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.